4//SEC Filing
Regnante Keith 4
Accession 0001209191-24-001155
CIK 0001664710other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:43 PM ET
Size
8.9 KB
Accession
0001209191-24-001155
Insider Transaction Report
Form 4
Regnante Keith
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2023-11-04$16.00/sh+40,000$640,000→ 40,000 total - Sale
Common Stock
2023-11-04$45.29/sh−40,000$1,811,600→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-01-04−40,000→ 53,622 totalExercise: $16.00Exp: 2030-04-06→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
- [F2]One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001682068
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 4:43 PM ET
- Size
- 8.9 KB